tert-butyl 4-(3-(4-chlorophenyl)-1,2,4-oxadiazole-5-yl)piperidine-1-carboxylate | 276236-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 4-(3-(4-chlorophenyl)-1,2,4-oxadiazole-5-yl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate
• CAS: 276236-88-5
• 化学式: C₁₈H₂₂ClN₃O₃
• 分子量: 363.844
• InChiKey: DXHPACHLDPKWGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  68.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-(4-chlorophenyl)-1,2,4-oxadiazole-5-yl)piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-[3-(4-chlorophenyl)[1,2,4]oxadiazol-5-yl]piperidine hydrochloride
  参考文献：
  名称：

  Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.

  DOI：

  10.1021/jm200825u
• 作为产物：
  描述：

  4-氯-N-羟基苯羧酰亚胺 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 tert-butyl 4-(3-(4-chlorophenyl)-1,2,4-oxadiazole-5-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.

  DOI：

  10.1021/jm200825u

文献信息

• A convenient and mild method for 1,2,4-oxadiazole preparation: cyclodehydration of O -acylamidoximes in the superbase system MOH/DMSO
  作者：Sergey Baykov、Tatyana Sharonova、Angelina Osipyan、Sergey Rozhkov、Anton Shetnev、Alexey Smirnov

  DOI：10.1016/j.tetlet.2016.05.071

  日期：2016.6

  Herein, we reported a general, convenient, and efficient synthesis of 3,5-disubstituted-1,2,4-oxadiazoles via cyclodehydration of O-acylamidoximes in the superbase system MOH/DMSO (M = Li, Na, K). Excellent isolated yields (up to 98%) were attained within short reaction times (10–20 min). In addition, mild reaction conditions and a simple work-up procedure allow the synthesis of a wide range of heat-labile

  在本文中，我们报道了在超碱系统MOH / DMSO（M = Li，Na，K）中通过O-酰基酰胺基肟的环脱水作用，一种一般，便捷，有效的合成3,5-二取代-1,2,4-恶二唑的方法。在较短的反应时间内（10-20分钟）即可获得出色的分离产率（高达98％）。此外，温和的反应条件和简单的后处理程序可以合成多种热不稳定的含1,2,4-恶二唑的物质。
• GPCR Agonists
  申请人：Edward Stuart

  公开号：US20090325924A1

  公开（公告）日：2009-12-31

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物式(I)或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
  作者：Marion Flipo、Matthieu Desroses、Nathalie Lecat-Guillet、Baptiste Villemagne、Nicolas Blondiaux、Florence Leroux、Catherine Piveteau、Vanessa Mathys、Marie-Pierre Flament、Juergen Siepmann、Vincent Villeret、Alexandre Wohlkönig、René Wintjens、Sameh H. Soror、Thierry Christophe、Hee Kyoung Jeon、Camille Locht、Priscille Brodin、Benoit Déprez、Alain R. Baulard、Nicolas Willand

  DOI：10.1021/jm200825u

  日期：2012.1.12

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.